Peripheral Arterial Disease (PAD) - Market Insights, Epidemiology and Market Forecast- 2027

Albany, NY -- (SBWire) -- 12/26/2018 --DelveInsight has announced the addition of the "Peripheral arterial disease (PAD) - Market Insights, Epidemiology and Market Forecast- 2027" drug pipelines to their offering.

Request for sample pages

The report provides an overview of the disease and market size of Peripheral arterial disease (PAD) for the seven major markets i.e., the United States, EU5 (France, Germany, Italy, Spain, the UK) and Japan. The Report also covers the overview, treatment practices and Peripheral arterial disease (PAD) forecasted epidemiology from 2018 to 2027, segmented by seven major markets.

Peripheral Arterial Disease (PAD) is a chronic disease and part of a global vascular problem of diffuse atherosclerosis in which plaque builds up in the arteries serving the legs, stomach, arms and head ("Peripheral" in this case means away from the heart, in the outer regions of the body). Building up of fatty deposits in the arteries restrict blood supply to peripheral organs, mostly affect the arteries of the legs. This fatty matter causes slight injury to artery walls with the release of chemicals that make the walls stickier. To this stickier walls, other floating substances, such as inflammatory cells, proteins and calcium accumulate and forms a plaque or atherosclerosis which narrows the artery. The disease develops gradually, but with progression, the blood flow in specific artery become limited or blocked all together. It is also known as peripheral vascular disease (PVD) and associated with cardiac and cerebrovascular-related events along with lower extremities obstruction. Women and men develop the condition equally.

Approximately more than half of the patients with PAD are asymptomatic, which make it difficult to estimate its true prevalence, but based on various population-based study reports, progressive increase in prevalence observed in persons older than 40 years of age, and mostly associated with cardiovascular risk factors, such as smoking, diabetes, hypertension, hypercholesterolemia and impaired kidney function in all countries. The ankle–brachial index is the most appropriate measure to use in describing the global distribution of PAD. It generally affects 12%–14% of the general population and its prevalence increases with age. The worldwide estimates indicate that the greatest numbers of patients with PAD are in Southeast Asia and Western Pacific regions. Along with cardiovascular risk factors, the environmental factors play major role in the development of PAD. It affects more than 10 million people in the U.S affecting approximately 12-20 percent of Americans over 60, but can occur at nearly any age.

Geography Covered

1. The United States
2. EU5 (Germany, France, Italy, Spain and the United Kingdom)
3. Japan

Study Period: 2016-2027

Drug Companies

1. Novartis
2. Rexgenero
3. Bayer
4. Shenzhen Salubris Pharmaceuticals
And many others

Drugs covered

1. REX-001
2. Recombinant SeV-hFGF2/dF
And many others

Report Scope
The report covers a descriptive overview of the Peripheral arterial disease (PAD) explaining its causes and currently available therapies. Comprehensive insight has been provided into the epidemiology of the Peripheral arterial disease (PAD) disease and its treatment in the 7 MM, covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan. Additionally, an all-inclusive account of both the current and emerging therapies for Peripheral arterial disease (PAD) are provided, along with assessment of the impact of new therapies will have on the current treatment landscape. A detailed review of global historical and forecasted Peripheral arterial disease (PAD) market is included in the report, covering drug outreach in 7 MM. The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Peripheral arterial disease (PAD) market